{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:18:08Z","timestamp":1775841488133,"version":"3.50.1"},"reference-count":98,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:00:00Z","timestamp":1609286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Nintedanib is a synthetic orally active tyrosine kinase inhibitor, whose main action is to inhibit the receptors of the platelet-derived growth factor, fibroblast growth factor and vascular endothelial growth factor families. The drug also affects other kinases, including Src, Flt-3, LCK, LYN. Nintedanib is used in the treatment of idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases and lung cancer. The mechanism of action suggests that nintedanib should be considered one of the potential agents for inhibiting and revising the fibrosis process related to COVID-19 infections. Due to the known induction of coagulation pathways during COVID-19 infections, possible interaction between nintedanib and anticoagulant seems to be an extremely important issue. In theory, nintedanib could increase the bleeding risk, thrombosis and lead to thrombocytopenia. The data from clinical trials on the concomitant use of nintedanib and antithrombotic agents is very limited as this patient group was within the standard exclusion criteria. Nintedanib is an important therapeutic option, despite its interaction with anticoagulants. If anticoagulant therapy is necessary, the more effective and safer option is the concomitant administration of DOACs and nintedanib, especially when drug-monitored therapy will be used in patients at high risk of bleeding complications.<\/jats:p>","DOI":"10.3390\/ijms22010282","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T09:35:23Z","timestamp":1609320923000},"page":"282","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["The Interactions of Nintedanib and Oral Anticoagulants\u2014Molecular Mechanisms and Clinical Implications"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6669-5931","authenticated-orcid":false,"given":"Grzegorz","family":"Grze\u015bk","sequence":"first","affiliation":[{"name":"Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru\u0144, 87-100 Toru\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Wo\u017aniak-Wi\u015bniewska","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru\u0144, 87-100 Toru\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"B\u0142a\u017cejewski","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru\u0144, 87-100 Toru\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartosz","family":"G\u00f3rny","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru\u0144, 87-100 Toru\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Wo\u0142owiec","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru\u0144, 87-100 Toru\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8440-902X","authenticated-orcid":false,"given":"Daniel","family":"Rogowicz","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru\u0144, 87-100 Toru\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4945-2369","authenticated-orcid":false,"given":"Alicja","family":"Nowaczyk","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru\u0144, 2 dr. A. Jurasza St., 85-094 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1021\/jm501562a","article-title":"Nintedanib: From Discovery to the Clinic","volume":"58","author":"Roth","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/14656566.2018.1425681","article-title":"Nintedanib for the treatment of idiopathic pulmonary fibrosis","volume":"19","author":"Varone","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_3","unstructured":"(2020, December 23). Anatomical Therapeutic Chemical Classification System. Available online: http:\/\/www.atccode.com\/."},{"key":"ref_4","unstructured":"(2020, December 23). J84.112\u2014Idiopathic Pulmonary Fibrosis. Available online: https:\/\/www.unboundmedicine.com\/icd\/view\/ICD-10-CM\/881192\/all\/J84_112___Idiopathic_pulmonary_fibrosis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10428","DOI":"10.1074\/jbc.RA119.007682","article-title":"Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib","volume":"294","author":"Terzyan","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_7","unstructured":"Therapeutic Goods Administration (Australia) (2020, December 23). Extract from the Clinical Evaluation Report for Nintedanib Esilate, Available online: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-nintedanib-esilate-60208-cer.pdf."},{"key":"ref_8","unstructured":"FDA Center for Drug Evaluation and Research (2020, December 23). Nintedanib Clinical Pharmacology NDA Review, Available online: http:\/\/www.accessdata.fda.gov\/drugsatfdadocs\/nda\/2014\/205832Orig1s000ClinPharmR.pdf."},{"key":"ref_9","unstructured":"European Medicines Agency (2020, December 23). Ofev. Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/documents\/product-information\/ofev-epar-product-information_en.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40265-014-0335-0","article-title":"Nintedanib: First global approval","volume":"75","author":"McCormack","year":"2015","journal-title":"Drugs"},{"key":"ref_11","unstructured":"European Medicines Agency (2020, December 23). Committee for Medicinal Products for Human Use (CHMP) Assessment Report for Ofev (Nintedanib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ofev-epar-public-assessment-report_en.pdf."},{"key":"ref_12","unstructured":"(2020, December 23). FDA Approves First Treatment for Group of Progressive Interstitial Lung Diseases U.S. Food and Drug Administration (FDA), Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-group-progressive-interstitial-lung-diseases."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.tibs.2014.08.010","article-title":"Feedback and redundancy in receptor tyrosine kinase signaling: Relevance to cancer therapies","volume":"39","author":"Sun","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signaling by receptor tyrosine kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1098\/rstb.1998.0228","article-title":"The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: Its role in cell growth and disease","volume":"353","author":"Hunter","year":"1998","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.tips.2014.09.007","article-title":"Advances in kinase targeting: Current clinical use and clinical trials","volume":"35","author":"Zhang","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2018.04.020","article-title":"The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders","volume":"133","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1021\/cb300663j","article-title":"Strategies for the selective regulation of kinases with allosteric modulators: Exploiting exclusive structural features","volume":"8","author":"Fang","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.resinv.2018.09.001","article-title":"Resistance to molecularly targeted therapy in non-small-cell lung cancer","volume":"57","author":"Asao","year":"2019","journal-title":"Respir. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12943-018-0793-1","article-title":"EGFR-TKIs resistance via EGFR-independent signaling pathways","volume":"17","author":"Liu","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1021\/cb500870a","article-title":"Targeting conformational plasticity of protein kinases","volume":"10","author":"Tong","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","article-title":"Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy","volume":"12","author":"Qin","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3322\/caac.20003","article-title":"Novel agents on the horizon for cancer therapy","volume":"59","author":"Ma","year":"2009","journal-title":"CA Cancer J. Clin."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tips.2013.11.004","article-title":"Molecularly targeted cancer therapy: Some lessons from the past decade","volume":"35","author":"Huang","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrd4025","article-title":"New anti-inflammatory targets for chronic obstructive pulmonary disease","volume":"12","author":"Barnes","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus Kinase (JAK) inhibitors for inflammatory diseases: Miniperspective","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nature13887","article-title":"An ERK\/Cdk5 axis controls the diabetogenic actions of PPAR\u03b3","volume":"517","author":"Banks","year":"2015","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5603\/ARM.46993","article-title":"Nintedanib\u2014nowa opcja terapeutyczna dla chorych na samoistne w\u0142\u00f3knienie p\u0142uc","volume":"84","author":"Majewski","year":"2016","journal-title":"Adv. Respir. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.2147\/OTT.S78805","article-title":"Profile of nintedanib in the treatment of solid tumors: The evidence to date","volume":"8","author":"Awasthi","year":"2015","journal-title":"Oncotargets Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2014.03.017","article-title":"Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity","volume":"61","author":"Tai","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9181","DOI":"10.1021\/ja202726y","article-title":"How does a drug molecule find its target binding site?","volume":"133","author":"Shan","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40262-019-00766-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of nintedanib","volume":"58","author":"Wind","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1126\/science.276.5314.955","article-title":"Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors","volume":"276","author":"Mohammadi","year":"1997","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.bbrc.2016.06.117","article-title":"Structural and biochemical studies of the PDGFRA kinase domain","volume":"477","author":"Liang","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0801-5","article-title":"Advances in studies of tyrosine kinase inhibitors and their acquired resistance","volume":"17","author":"Jiao","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/00498254.2010.545452","article-title":"Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers","volume":"41","author":"Stopfer","year":"2011","journal-title":"Xenobiotica"},{"key":"ref_44","unstructured":"Boehringer Ingelheim (2020, December 23). OFEV\u00ae (Nintedanib) Capsules, for Oral Use [package Insert]. Ridgefield: Boehringer Ingelheim Pharmaceuticals. Available online: http:\/\/docs.boehringer-ingelheim.com\/Prescribing.Information\/PIs\/Ofev\/ofev.pdf."},{"key":"ref_45","unstructured":"(2020, December 23). Nintedanib ChPL Aneks. Available online: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2015\/20150115130436\/anx_130436_pl.pdf."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13318-018-0467-9","article-title":"Effects of ketoconazole and rifampicin on the pharmacokinetics of nintedanib in healthy subjects","volume":"43","author":"Luedtke","year":"2018","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000495046","article-title":"Nintedanib in idiopathic pulmonary fibrosis: Practical management recommendations for potential adverse events","volume":"97","author":"Bendstrup","year":"2019","journal-title":"Respiration"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Hughes, G., Toellner, H., Morris, H., Leonard, C., and Chaudhuri, N. (2016). Real world experiences: Pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J. Clin. Med., 5.","DOI":"10.3390\/jcm5090078"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12931-015-0276-5","article-title":"Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis","volume":"16","author":"Corte","year":"2015","journal-title":"Respir. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2217\/lmt.15.33","article-title":"Nintedanib in advanced NSCLC: Management of adverse events","volume":"5","author":"Lemmens","year":"2016","journal-title":"Lung Cancer Manag."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.lungcan.2015.08.003","article-title":"Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel","volume":"90","author":"Reck","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S2213-2600(18)30339-4","article-title":"Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: Results from the open-label extension study, INPULSIS-ON","volume":"7","author":"Crestani","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e000397","DOI":"10.1136\/bmjresp-2018-000397","article-title":"Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: Pooled data from six clinical trials","volume":"6","author":"Lancaster","year":"2019","journal-title":"BMJ Open Respir. Res."},{"key":"ref_55","first-page":"19","article-title":"Efficacy and safety of nintedanib for the treatment of idiopathic pulmonary fibrosis: An update","volume":"18","year":"2018","journal-title":"Drugs"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Case, A.H., and Johnson, P. (2017). Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis. BMJ Open Respir. Res., 4.","DOI":"10.1136\/bmjresp-2017-000192"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000485933","article-title":"Real-world experience with nintedanib in patients with idiopathic pulmonary fibrosis","volume":"95","author":"Brunnemer","year":"2018","journal-title":"Respiration"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/eurheartj\/eht134","article-title":"EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: Executive summary","volume":"34","author":"Heidbuchel","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.5603\/KP.2016.0172","article-title":"Wytyczne ESC dotycz\u0105ce leczenia migotania przedsionk\u00f3w w 2016 roku, opracowane we wsp\u00f3\u0142pracy z EACTS","volume":"74","author":"Kirchhof","year":"2016","journal-title":"Kardiol. Pol."},{"key":"ref_61","first-page":"43","article-title":"The latest recommendations on the use of new oral anticoagulants in routine practice","volume":"70","author":"Witkowski","year":"2016","journal-title":"Adv. Hyg. Exp. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","article-title":"Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation\u2013Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF\u2013TIMI 48)","volume":"160","author":"Ruff","year":"2010","journal-title":"Am. Heart J."},{"key":"ref_63","first-page":"201","article-title":"Atrial fibrillation\u2014The most common arrhythmia in older age. Differences of anticoagulation treatment","volume":"26","author":"Zapolski","year":"2018","journal-title":"Gerontol. Pol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Cohen, A., Hamilton, M., Mitchell, S., Phatak, H., Liu, X., Bird, A., Tushabe, D., and Batson, S. (2015). Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: Systematic review and network meta-analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144856"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.arth.2016.09.033","article-title":"Safety and efficacy of new anticoagulants for the prevention of venous thromboembolism after hip and knee arthroplasty: A meta-analysis","volume":"32","author":"Venker","year":"2017","journal-title":"J. Arthroplast."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjh.14714","article-title":"Current challenges and future prospects in oral anticoagulant therapy","volume":"178","author":"Czuprynska","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.clinthera.2017.05.358","article-title":"Effectiveness and safety of non\u2013vitamin k antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: A systematic review and meta-analyses","volume":"39","author":"Almutairi","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pjnns.2015.04.007","article-title":"Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice","volume":"49","author":"Zawilska","year":"2015","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cjca.2014.08.001","article-title":"2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation","volume":"30","author":"Verma","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1160\/TH13-07-0552","article-title":"Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial","volume":"110","author":"Apostolakis","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_75","first-page":"3258","article-title":"The ORBIT bleeding score: A simple bedside score to assess bleeding risk in atrial fibrillation","volume":"36","author":"Simon","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ahj.2009.02.005","article-title":"Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran","volume":"157","author":"Ezekowitz","year":"2009","journal-title":"Am. Heart J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"ref_78","unstructured":"J\u0119drusik, P., and Gaciong, Z. (2017). Post\u0119powanie w Przypadku Krwawienia Podczas Leczenia Przeciwzakrzepowego. Swoiste Czynniki Odwracaj\u0105ce Dzia\u0142anie Lek\u00f3w z Grupy NOAC, PZWL."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2014Full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_81","first-page":"1","article-title":"Andeksanet alfa\u2014Wyczekiwane swoiste antidotum w krwawieniach spowodowanych przez ksabany","volume":"10","year":"2018","journal-title":"Med. Trib."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.amjmed.2016.06.009","article-title":"Preclinical and clinical data for factor Xa and \u201cuniversal\u201d reversal agents","volume":"129","author":"Milling","year":"2016","journal-title":"Am. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.thromres.2016.07.008","article-title":"Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin","volume":"146","author":"Ansell","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","article-title":"Use of PER977 to reverse the anticoagulant effect of edoxaban","volume":"371","author":"Ansell","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: Their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_86","first-page":"93","article-title":"Monitorowanie leczenia nowymi doustnymi antykoagulantami\u2014kiedy, dlaczego i jakimi metodami?","volume":"7","author":"Zawilska","year":"2014","journal-title":"J. Transfus. Med."},{"key":"ref_87","first-page":"1","article-title":"12 najcz\u0119stszych sytuacji klinicznych zwi\u0105zanych ze stosowaniem NOAC u pacjent\u00f3w z AF po uwzgl\u0119dnieniu wytycznych ESC z 2016 r","volume":"6","author":"Balsam","year":"2017","journal-title":"Kardiol. Dyplomie"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.5603\/KP.a2018.0194","article-title":"Adherence in patients with atrial fibrillation treated with dabigatran","volume":"76","author":"Janiszewska","year":"2018","journal-title":"Kardiol. Pol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bjh.12975","article-title":"Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology","volume":"166","author":"Kitchen","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.blre.2016.08.006","article-title":"Measurement and reversal of the direct oral anticoagulants","volume":"31","author":"Samuelson","year":"2017","journal-title":"Blood Rev."},{"key":"ref_91","first-page":"161","article-title":"Oznaczanie aktywno\u015bci antykoagulacyjnej bezpo\u015brednich doustnych antykoagulant\u00f3w\u2013aktualny stan wiedzy i do\u015bwiadczenia w\u0142asne laboratorium","volume":"53","author":"Undas","year":"2017","journal-title":"Diagn. Lab."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/00365513.2018.1522664","article-title":"Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays","volume":"78","author":"Hillarp","year":"2018","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1373\/clinchem.2012.189704","article-title":"The laboratory and the new oral anticoagulants","volume":"59","author":"Tripodi","year":"2013","journal-title":"Clin. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"377","DOI":"10.5603\/FC.2016.0064","article-title":"Doustne antykoagulanty nowej generacji\u2014Aspekty praktyczne. Stanowisko Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego","volume":"11","author":"Kasprzak","year":"2016","journal-title":"Folia Cardiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1515\/cclm-2014-0767","article-title":"Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): Is there consensus?","volume":"53","author":"Lippi","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_96","first-page":"221","article-title":"Doustne antykoagulanty o dzia\u0142aniu bezpo\u015brednim\u2013nowe wyzwanie dla diagnostyki laboratoryjnej","volume":"51","author":"Michno","year":"2015","journal-title":"Diagn. Lab."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1164\/rccm.201202-0314OC","article-title":"Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis","volume":"186","author":"Noth","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1002\/art.24935","article-title":"Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts","volume":"60","author":"Bogatkevich","year":"2009","journal-title":"Arthritis Rheum."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/1\/282\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:47:42Z","timestamp":1760179662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/1\/282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,30]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["ijms22010282"],"URL":"https:\/\/doi.org\/10.3390\/ijms22010282","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,30]]}}}